Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Change in Account Payables (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Change in Account Payables data on record, last reported at $750000.0 in Q3 2025.

  • For Q3 2025, Change in Account Payables rose 293.3% year-over-year to $750000.0; the TTM value through Sep 2025 reached $1.8 million, up 251.13%, while the annual FY2024 figure was $797000.0, 374.83% up from the prior year.
  • Change in Account Payables reached $750000.0 in Q3 2025 per SNTI's latest filing, up from -$537000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.2 million in Q4 2024 and bottomed at -$2.3 million in Q4 2021.
  • Average Change in Account Payables over 5 years is -$56072.3, with a median of $85.0 recorded in 2021.
  • The widest YoY moves for Change in Account Payables: up 8718.97% in 2022, down 585814.29% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at -$2.3 million in 2021, then surged by 103.99% to $93000.0 in 2022, then crashed by 911.83% to -$755000.0 in 2023, then soared by 264.11% to $1.2 million in 2024, then crashed by 39.47% to $750000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $750000.0 in Q3 2025, -$537000.0 in Q2 2025, and $357000.0 in Q1 2025.